Suppression of BRAFV599E in human melanoma abrogates transformation

Cancer Research

Volumn 63, Issue 17, 2003, Pages 5198-5202

  Hingorani, Sunil R ^a,b   Jacobetz, Michael A ^a   Robertson, Gavin P ^d   Herlyn, Meenhard ^c   Tuveson, David A ^a,c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Department of Medicine ^*  (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN BRAF V599E; PROTEIN CRAF; PROTEIN SERINE THREONINE KINASE; RNA; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL CULTURE; CELL VIABILITY; COLONY FORMATION; ENZYME INHIBITION; FIBROSARCOMA; GENE MUTATION; GENE REPRESSION; HUMAN; HUMAN CELL; MALIGNANT TRANSFORMATION; MELANOMA; PHENOTYPE; PRIORITY JOURNAL;

CELL ADHESION; CELL DIVISION; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; MELANOMA; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-RAF; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0141816881     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Jemal, A., Murray, T., Samuels, A., Ghafoor, A., Ward, E., and Thun, M. J. Cancer statistics, 2003. CA Cancer J. Clin., 53: 5-26, 2003.
2. Jemal, A., Devesa, S. S., Hartge, P., and Tucker, M. A. Recent trends in cutaneous melanoma incidence among whites in the United States. J. Natl. Cancer Inst. (Bethesda), 93: 678-683, 2001.
3. Balch, C. M., Buzaid, A. C., Soong, S. J., Atkins, M. B., Cascinelli, N., Coit, D. G., Fleming, I. D., Gershenwald, J. E., Houghton, A., Jr., Kirkwood, J. M., McMasters, K. M., Mihm, M. F., Morton, D. L., Reintgen, D. S., Ross, M. I., Sober, A., Thompson, J. A., and Thompson, J. F. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J. Clin. Oncol., 19: 3635-3648, 2001.
4. Brose, M. S., Volpe, P., Feldman, M., Kumar, M., Rishi, I., Gerrero, R., Einhorn, E., Herlyn, M., Minna, J., Nicholson, A., Roth, J. A., Albelda, S. M., Davies, H., Cox, C., Brignell, G., Stephens, P., Futreal, P. A., Wooster, R., Stratton, M. R., and Weber, B. L. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res., 62: 6997-7000, 2002.
5. Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., Davis, N., Dicks, E., Ewing, R., Floyd, Y., Gray, K., Hall, S., Hawes, R., Hughes, J., Kosmidou, V., Menzies, A., Mould, C., Parker, A., Stevens, C., Watt, S., Hooper, S., Wilson, R., Jayatilake, H., Gusterson, B. A., Cooper, C., Shipley, J., Hargrave, D., Pritchard-Jones, K., Maitland, N., Chenevix-Trench, G., Riggins, G. J., Bigner, D. D., Palmieri, G., Cossu, A., Flanagan, A., Nicholson, A., Ho, J. W., Leung, S. Y., Yuen, S. T., Weber, B. L., Seigler, H. F., Darrow, T. L., Paterson, H., Marais, R., Marshall, C. J., Wooster, R., Stratton, M. R., and Futreal, P. A. Mutations of the BRAF gene in human cancer. Nature (Lond.), 417: 949-954, 2002.
6. Pollock, P. M., Harper, U. L., Hansen, K. S., Yudt, L. M., Stark, M., Robbins, C. M., Moses, T. Y., Hostetter, G., Wagner, U., Kakareka, J., Salem, G., Pohida, T., Heenan, P., Duray, P., Kallioniemi, O., Hayward, N. K., Trent, J. M., and Meltzer, P. S. High frequency of BRAF mutations in nevi. Nat. Genet., 33: 19-20, 2003.
7. Hagemann, C., and Rapp, U. R. Isotype-specific functions of Raf kinases. Exp. Cell Res., 253: 34-46, 1999.
8. Elbashir, S. M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., and Tuschl, T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature (Lond.), 411: 494-498, 2001.
9. Elbashir, S. M., Harborth, J., Weber, K., and Tuschl, T. Analysis of gene function in somatic mammalian cells using small interfering RNAs. Methods, 26: 199-213, 2002.
10. Satyamoorthy, K., DeJesus, E., Linnenbach, A. J., Kraj, B., Kornreich, D. L., Rendle, S., Elder, D. E., and Herlyn, M. Melanoma cell lines from different stages of progression and their biological and molecular analyses. Melanoma Res., 7 (Suppl. 2): S35-S42, 1997.
11. Brummelkamp, T. R., Bernards, R., and Agami, R. A system for stable expression of short interfering RNAs in mammalian cells. Science, 296: 550-553, 2002.
12. Paddison, P. J., Caudy, A. A., and Hannon, G. J. Stable suppression of gene expression by RNAi in mammalian cells. Proc. Natl. Acad. Sci. USA, 99: 1443-1448, 2002.
13. Hannon, G. J. RNA interference. Nature (Lond.), 418: 244-251, 2002.
14. Satyamoorthy, K., Li, G., Gerrero, M. R., Brose, M. S., Volpe, P., Weber, B. L., Van Belle, P., Elder, D. E., and Herlyn, M. Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res., 63: 756-759, 2003.
15. Hanahan, D., and Weinberg, R. A. The hallmarks of cancer. Cell, 100: 57-70, 2000.
16. Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., and Sawyers, C. L. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med., 344: 1031-1037, 2001.
17. Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., Fletcher, J. A., Silverman, S. G., Silberman, S. L., Capdeville, R., Kiese, B., Peng, B., Dimitrijevic, S., Druker, B. J., Corless, C., Fletcher, C. D., and Joensuu, H. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Eng. J. Med., 347: 472-480, 2002.
18. Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., and Sawyers, C. L. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science (Wash. DC), 293: 876-880, 2001.
19. Tuveson, D. A., Willis, N. A., Jacks, T., Griffin, J. D., Singer, S., Fletcher, C. D., Fletcher, J. A., and Demetri, G. D. STI571 inactivation of the gastrointestinal stromat tumor c-KIT oncoprotein: biological and clinical implications. Oncogene, 20: 5054-5058, 2001.
20. Lyons, J. F., Wilhelm, S., Hibner, B., and Bollag, G. Discovery of a novel Raf kinase inhibitor. Endocrine-Related Cancer, 8: 219-225, 2001.
21. Oldham, S. M., Clark, G. J., Gangarosa, L. M., Coffey, R. J., Jr., and Der, C. J. Activation of the Raf-1/MAP kinase cascade is not sufficient for Ras transformation of RIE-1 epithelial cells. Proc. Natl. Acad. Sci. USA, 93: 6924-6928, 1996.
22. Mercer, K. E., and Pritchard, C. A. Raf proteins and cancer: B-Raf is identified as a mutational target. Biochim. Biophys. Acta, 1653: 25-40, 2003.